
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc. demonstrates a promising outlook based on recent clinical trial data, particularly from the VERITAC-2 study, which revealed a statistically significant improvement in median progression-free survival (mPFS) for patients with ESR1 mutations, positioning the company favorably against competitors. The data also indicate that vepdegestrant (vepdeg) shows compelling differentiation and competitiveness, potentially exceeding a 4-month mPFS in the ESR1 mutant population, which could enhance its market position in monotherapy scenarios. Furthermore, the combination treatment with vepdeg has been deemed safe, with no dose-limiting toxicities or severe adverse events, bolstering confidence in its therapeutic potential.
Bears say
The financial outlook for Arvinas Inc appears negative due to several fundamental concerns regarding the efficacy and competitive positioning of its product candidates, particularly bavdegalutamide and vepdegestrant. There is apprehension over the restricted label likely resulting from insufficient benefit in the intent-to-treat population, which could hinder commercialization and push back clinical evidence timelines. Additionally, uncertainties surrounding pipeline momentum and the potential for new competitors to seize market share in earlier treatment lines further cloud the company’s revenue projections and overall growth potential.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares